Amgen, Inc. Forecasted to Post FY2019 Earnings of $14.64 Per Share (NASDAQ:AMGN)

Share on StockTwits

Amgen, Inc. (NASDAQ:AMGN) – Stock analysts at Oppenheimer boosted their FY2019 earnings estimates for Amgen in a research report issued to clients and investors on Sunday, December 1st. Oppenheimer analyst J. Olson now forecasts that the medical research company will post earnings of $14.64 per share for the year, up from their previous estimate of $14.30. Oppenheimer has a “Buy” rating and a $240.00 price objective on the stock. Oppenheimer also issued estimates for Amgen’s FY2021 earnings at $18.83 EPS, FY2022 earnings at $19.65 EPS and FY2023 earnings at $20.50 EPS.

Other analysts have also recently issued reports about the company. Sanford C. Bernstein initiated coverage on Amgen in a research report on Monday, October 14th. They issued an “outperform” rating on the stock. Goldman Sachs Group set a $243.00 price target on Amgen and gave the stock a “buy” rating in a research report on Monday, September 30th. Leerink Swann increased their price target on Amgen from $189.00 to $205.00 and gave the stock a “market perform” rating in a research note on Wednesday, October 30th. Mizuho restated a “hold” rating and set a $212.00 price target on shares of Amgen in a research report on Sunday, September 29th. Finally, BidaskClub raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, November 13th. Ten equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $221.47.

AMGN opened at $233.48 on Tuesday. The company has a quick ratio of 2.59, a current ratio of 2.89 and a debt-to-equity ratio of 2.54. The firm has a market cap of $139.47 billion, a price-to-earnings ratio of 16.21, a price-to-earnings-growth ratio of 2.37 and a beta of 1.12. Amgen has a fifty-two week low of $166.30 and a fifty-two week high of $235.80. The company’s 50-day moving average price is $217.12 and its 200 day moving average price is $194.79.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, October 29th. The medical research company reported $3.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.53 by $0.13. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.63 billion. Amgen had a return on equity of 80.26% and a net margin of 34.48%. The company’s revenue for the quarter was down 2.8% compared to the same quarter last year. During the same quarter last year, the firm earned $3.69 earnings per share.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Advisors Preferred LLC purchased a new stake in shares of Amgen in the 2nd quarter valued at approximately $30,000. Balentine LLC raised its stake in Amgen by 36.1% during the 3rd quarter. Balentine LLC now owns 181 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 48 shares during the period. Atwater Malick LLC acquired a new stake in Amgen during the 3rd quarter valued at $39,000. Ashburton Jersey Ltd purchased a new stake in shares of Amgen in the second quarter valued at $42,000. Finally, Next Capital Management LLC lifted its holdings in shares of Amgen by 42.5% in the second quarter. Next Capital Management LLC now owns 238 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 71 shares in the last quarter. Institutional investors and hedge funds own 76.64% of the company’s stock.

In other news, EVP Jonathan P. Graham sold 9,000 shares of the stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $230.54, for a total transaction of $2,074,860.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronald D. Sugar sold 2,000 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $206.70, for a total value of $413,400.00. Following the sale, the director now directly owns 16,336 shares of the company’s stock, valued at $3,376,651.20. The disclosure for this sale can be found here. Insiders have sold 22,162 shares of company stock valued at $5,014,590 over the last 90 days. 0.25% of the stock is currently owned by insiders.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 6th. Investors of record on Friday, November 15th will be issued a dividend of $1.45 per share. This represents a $5.80 dividend on an annualized basis and a yield of 2.48%. The ex-dividend date is Thursday, November 14th. Amgen’s payout ratio is 40.28%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Article: P/E Growth (PEG)

Earnings History and Estimates for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.